Tokai Pharmaceuticals Inc. (Nasdaq: TKAI) will discontinue a late-stage study of its prostate cancer treatment. The stock price collapsed $4.10 to close at $1.10.
Tokai Pharmaceuticals discontinues study
July 26, 2016 at 18:25 PM EDT
Tokai Pharmaceuticals discontinues studyJuly 26, 2016 at 18:25 PM EDT
Tokai Pharmaceuticals Inc. (Nasdaq: TKAI) will discontinue a late-stage study of its prostate cancer treatment. The stock price collapsed $4.10 to close at $1.10.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|